LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Saved in:
Bibliographic Details
Published inHematological oncology Vol. 39; no. S2
Main Authors Zinzani, P. L., Caimi, P. F., Carlo‐Stella, C., Ai, W., Alderuccio, J. P., Ardeshna, K. M., Hess, B., Kahl, B. S., Radford, J., Solh, M., Stathis, A., Feingold, J., Ungar, D., Qin, Y., He, S., Hamadani, M.
Format Journal Article
LanguageEnglish
Published Chichester Wiley Subscription Services, Inc 01.06.2021
Subjects
B-cell lymphoma
Lymphoma
Monoclonal antibodies
Targeted cancer therapy
Online AccessGet full text

Cover

More Information
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.89_2880